ZETA- I AM NOT FAMILIAR WITH THIS NAME BUT I LOVE COMPANIES THAT MOVE DURING ANALYST DAYS-- THEY USUALLY HAVE EXTENDED UPSIDE. THIS COULD GO TO $10. Zeta Global up 3% as investor day meeting continues » 11:17 ZETA Zeta Global Holdings Corp. (ZETA) NYSE - Nasdaq Real Time Price. 8.19+0.27(+3.47%) As of 11:42AM EDT. Description Zeta Global Holdings Corp. operates an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software in the United States and internationally. The company's Zeta Marketing Platform analyzes billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing; and Consumer Data platform ingests, analyzes, and distills disparate data points to generate a single view of a consumer, encompassing identity, profile characteristics, behaviors, and purchase intent. It also offers various types of product suites, such as opportunity explorer, and CDP+, which helps in consolidating multiple databases and internal and external data feeds and organize data based on needs and performance metrics. Zeta Global Holdings Corp. was incorporated in 2007 and is headquartered in New York, New York.
Security TSLA PUT 09/29/2023 $240.00 Account Self-Directed Action Sell to close Order type Limit $4.60 Quantity XX Filled XX Time in force Day Status Fully executed Order number Order time/date 12:17 PM ET 09/27/2023 Security TSLA PUT 09/29/2023 $240.00 Account Self-Directed Action Buy to open Order type Limit $2.65 Quantity Filled XX Time in force Day Status Fully executed Order number Order time/date 9:56 AM ET 09/27/2023 I got 2.58 on the first batch I think.
PSTX did that yesterday. PSTX $2.50 Lots of strong buy ratings, target $12 They just had a cash infusion of $25M at $3/share. Under the terms of the transaction agreements, Astellas will invest a total of $50 million, including $25 million to acquire 8,333,333 shares of common stock of Poseida (approximately 8.8% of the outstanding common stock of Poseida) at $3.00 per share in a private placement and a one-time $25 million payment for a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs: P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications. In addition, Poseida has granted Astellas a board observer seat, which includes the ability to attend Poseida's scientific advisory board meetings, and certain notice rights related to any potential change of control of Poseida. Astellas has established the Focus Area Approach for its research and development strategy. One of Astellas' Primary Focuses within the strategy is immuno-oncology. Astellas is committed to developing next-generation immuno-oncology drugs using multi-functional platforms. Its portfolio includes oncolytic viruses, bispecific immune cell engagers, small molecules, and cell therapy platforms. Poseida is engaged in the research and development of cell and gene therapies for cancer and rare genetic diseases by leveraging its proprietary genetic editing platforms. In oncology, Poseida has a broad pipeline of allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, including P-MUC1C-ALLO1, which is in Phase 1 development for the treatment of multiple solid tumor indications. VOLUME WAY UP